The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

AstraZeneca's Durvalumab Gets US Designation In Bladder Cancer

Wed, 17th Feb 2016 07:11

LONDON (Alliance News) - AstraZeneca PLC said Wednesday that its drug durvalumab has been granted a breakthrough therapy designation by the US Food and Drug Administration for the treatment of PD-L1 positive urothelial bladder cancer.

This designation is given to speed up the development of new drugs that are intended to treat a serious condition, demonstrate a substantial improvement over available therapies, or where there is significant unmet medical need.

Durvalumab was granted this designation based on early clinical data from a phase I trial in patients with advanced metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.

The compound is also being tested in first-line bladder cancer on its own, as well as in combination with tremelimumab.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IN BRIEF: DeepMatter partners with universities on automated precision

IN BRIEF: DeepMatter partners with universities on automated precision

17 Jun 21 19:14

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

17 Jun 21 14:07

Thursday broker round-up

(Sharecast News) - Pets At Home: Liberum upgrades to buy with a target price of 510p.

17 Jun 21 13:49

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

17 Jun 21 09:48

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.